| 3.0095 0.08 (2.71%) | 10-30 14:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.84  |
1-year : | 4.36 |
| Resists | First : | 3.28 |
Second : | 3.74 |
| Pivot price | 2.93 |
|||
| Supports | First : | 2.55 | Second : | 2.12 |
| MAs | MA(5) : | 2.95  |
MA(20) : | 2.99 |
| MA(100) : | 4.6 |
MA(250) : | 6.27 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 53.4 |
D(3) : | 52.1 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 10.43 | Low : | 2.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ADXN ] has closed below upper band by 32.9%. Bollinger Bands are 63.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3 - 3.02 | 3.02 - 3.04 |
| Low: | 2.85 - 2.87 | 2.87 - 2.89 |
| Close: | 2.9 - 2.93 | 2.93 - 2.96 |
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Thu, 29 Oct 2026
Outstanding shares remain unchanged as Addex (ADXN) issues new shares to its wholly owned subsidiary. - Stock Titan
Sun, 25 Oct 2026
Addex Therapeutics Ltd Estimates – SIX:ADXN - TradingView
Thu, 08 Oct 2026
ADXN: Addex Therapeutics Ltd - ADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Wed, 30 Sep 2026
Addex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ... - Yahoo Finance
Sun, 27 Sep 2026
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update - Yahoo Finance
Fri, 21 Aug 2026
ADXN Stock Volatile As Traders Focus On Liquidity And Deep Losses - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 876300 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 4 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.6e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 487.2 % |
| Return on Equity (ttm) | -27.2 % |
| Qtrly Rev. Growth | 83070 % |
| Gross Profit (p.s.) | -36 |
| Sales Per Share | -74.55 |
| EBITDA (p.s.) | -134743 |
| Qtrly Earnings Growth | -7.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 2.78 |
| Dividend | 0 |
| Forward Dividend | 1840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|